These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28417953)

  • 1. Recombinant Adeno-Associated Virus-mediated rescue of function in a mouse model of Dopamine Transporter Deficiency Syndrome.
    Illiano P; Bass CE; Fichera L; Mus L; Budygin EA; Sotnikova TD; Leo D; Espinoza S; Gainetdinov RR
    Sci Rep; 2017 Apr; 7():46280. PubMed ID: 28417953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism.
    Ng J; Barral S; De La Fuente Barrigon C; Lignani G; Erdem FA; Wallings R; Privolizzi R; Rossignoli G; Alrashidi H; Heasman S; Meyer E; Ngoh A; Pope S; Karda R; Perocheau D; Baruteau J; Suff N; Antinao Diaz J; Schorge S; Vowles J; Marshall LR; Cowley SA; Sucic S; Freissmuth M; Counsell JR; Wade-Martins R; Heales SJR; Rahim AA; Bencze M; Waddington SN; Kurian MA
    Sci Transl Med; 2021 May; 13(594):. PubMed ID: 34011628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells.
    Beerepoot P; Lam VM; Salahpour A
    J Biol Chem; 2016 Oct; 291(42):22053-22062. PubMed ID: 27555326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Caenorhabditis elegans model to study dopamine transporter deficiency syndrome.
    Illiano P; Lanzo A; Leo D; Paglione M; Zampi G; Gainetdinov RR; Di Schiavi E
    Eur J Neurosci; 2017 Jan; 45(1):207-214. PubMed ID: 27519790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
    Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
    Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex differences in striatal dopaminergic function within heterozygous mutant dopamine transporter knock-out mice.
    Ji J; Dluzen DE
    J Neural Transm (Vienna); 2008 Jun; 115(6):809-17. PubMed ID: 18197357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
    J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of cocaine stimulation and reward by reintroducing wild type dopamine transporter in adult knock-in mice with a cocaine-insensitive dopamine transporter.
    Wu H; O'Neill B; Han DD; Thirtamara-Rajamani K; Wang Y; Gu HH
    Neuropharmacology; 2014 Nov; 86():31-7. PubMed ID: 24835281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pronounced Hyperactivity, Cognitive Dysfunctions, and BDNF Dysregulation in Dopamine Transporter Knock-out Rats.
    Leo D; Sukhanov I; Zoratto F; Illiano P; Caffino L; Sanna F; Messa G; Emanuele M; Esposito A; Dorofeikova M; Budygin EA; Mus L; Efimova EV; Niello M; Espinoza S; Sotnikova TD; Hoener MC; Laviola G; Fumagalli F; Adriani W; Gainetdinov RR
    J Neurosci; 2018 Feb; 38(8):1959-1972. PubMed ID: 29348190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-related changes in nigrostriatal dopaminergic function in heterozygous mutant dopamine transporter knock-out mice.
    Dluzen DE; Ji J; McDermott JL
    Neurosci Lett; 2010 May; 476(2):66-9. PubMed ID: 20382201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.
    Khodr CE; Becerra A; Han Y; Bohn MC
    Brain Res; 2014 Mar; 1550():47-60. PubMed ID: 24463035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiscale imaging characterization of dopamine transporter knockout mice reveals regional alterations in spine density of medium spiny neurons.
    Berlanga ML; Price DL; Phung BS; Giuly R; Terada M; Yamada N; Cyr M; Caron MG; Laakso A; Martone ME; Ellisman MH
    Brain Res; 2011 May; 1390():41-9. PubMed ID: 21439946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects.
    Colella P; Sellier P; Gomez MJ; Biferi MG; Tanniou G; Guerchet N; Cohen-Tannoudji M; Moya-Nilges M; van Wittenberghe L; Daniele N; Gjata B; Krijnse-Locker J; Collaud F; Simon-Sola M; Charles S; Cagin U; Mingozzi F
    EBioMedicine; 2020 Nov; 61():103052. PubMed ID: 33039711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system.
    Barroso-Chinea P; Cruz-Muros I; Afonso-Oramas D; Castro-Hernández J; Salas-Hernández J; Chtarto A; Luis-Ravelo D; Humbert-Claude M; Tenenbaum L; González-Hernández T
    Neurobiol Dis; 2016 Apr; 88():44-54. PubMed ID: 26777664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter.
    Manning-Boğ AB; Caudle WM; Perez XA; Reaney SH; Paletzki R; Isla MZ; Chou VP; McCormack AL; Miller GW; Langston JW; Gerfen CR; Dimonte DA
    Neurobiol Dis; 2007 Aug; 27(2):141-50. PubMed ID: 17560790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model.
    Qi X; Davis B; Chiang YH; Filichia E; Barnett A; Greig NH; Hoffer B; Luo Y
    J Neurochem; 2016 Sep; 138(5):746-57. PubMed ID: 27317935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Tyrosine Hydroxylase Expression and Phosphorylation in Dopamine Transporter-Deficient Mice.
    Salvatore MF; Calipari ES; Jones SR
    ACS Chem Neurosci; 2016 Jul; 7(7):941-51. PubMed ID: 27124386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal tagging of the dopamine transporter impairs protein expression and trafficking in vivo.
    Vecchio LM; Bermejo MK; Beerepoot P; Ramsey AJ; Salahpour A
    Mol Cell Neurosci; 2014 Jul; 61():123-32. PubMed ID: 24886986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.